Esperion Therapeutics, Inc. (ESPR) To Provide ETC-1002 Program Update; Fourth Quarter And Full Year 2013 Financial Results
2/27/2014 8:21:18 AM
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast to provide program development updates and discuss financial results for the fourth quarter and full year ended Dec. 31, 2013. The webcast will take place following NASDAQ Market close on Wednesday, March 5, 2014 at 4:30 p.m. Eastern Time.
Help employers find you! Check out all the jobs and post your resume.
comments powered by